Rule 3.19A.2

# **Appendix 3Y**

# **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Patrys Limited
ABN	97 123 055 363

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Campbell
Date of last notice	6 December 2021

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Barrabool Biotechnology Pty Ltd <j a="" and="" c="" campbell="" family="" k="">  Dr. Campbell is a beneficiary of the above entity</j>
Date of change	4 August 2023

<sup>+</sup> See chapter 19 for defined terms.

[N. 4. W. 1	Τ
No. of securities held prior to change	Direct:
	17,383,125 Fully paid ordinary shares
	3,283 PABO Listed options, exercisable at
	\$0.024 (2.4 cents), expiring 5 August 2023
	335,522 PABOA Listed options,
	exercisable at \$0.04 (4 cents), expiring 15
	December 2023
	10,000,000 Unlisted options, exercisable
	at \$0.035, expiring on 22 November 2023
	11,000,000 Unlisted options, exercisable at
	\$0.027 (2.7 cents), expiring on 18 December 2024
	December 2024
	25,000,000 Unlisted options, exercisable
	at \$0.059 (5.9 cents), expiring on 30
	September 2025
	Indirect:
	1,502,000 Fully paid ordinary shares
	1,502,000 rung para oramary smares
	396,132 PABO Listed options, exercisable
	at \$0.024 (2.4 cents), expiring 5 August
	2023
	66,022 PABOA Listed options, exercisable
	at \$0.04 (4 cents), expiring 15 December
	2023
	PAROXI I
Class	PABO Listed options
Number acquired	
Number acquired	-
Number disposed	Direct:
	(1) 3,283 PABO Listed options
	Indirect:
	(2) 396,132 PABO Listed options
Value/Consideration	(1) N/A
Note: If consideration is non-cash, provide details and estimated valuation	(2) N/A

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.

No. of securities held after change	Direct:
	17,383,125 Fully paid ordinary shares
	335,522 PABOA Listed options, exercisable at \$0.04 (4 cents), expiring 15 December 2023
	10,000,000 Unlisted options, exercisable at \$0.035, expiring on 22 November 2023
	11,000,000 Unlisted options, exercisable at \$0.027 (2.7 cents), expiring on 18 December 2024
	25,000,000 Unlisted options, exercisable at \$0.059 (5.9 cents), expiring on 30 September 2025
	Indirect: 1,502,000 Fully paid ordinary shares
	66,022 PABOA Listed options, exercisable at \$0.04 (4 cents), expiring 15 December 2023
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of PABO Listed options.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	N/A

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y Change of Director's Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

# Part 3 – \*Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Appendix 3Y Page 4 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.